Archive for the ‘Trubion Pharmaceuticals’ Category
Emergent BioSolutions Completes Acquisition of Trubion Pharmaceuticals
ROCKVILLE, Md., Oct 28, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the acquisition of Trubion Pharmaceuticals, Inc., following a majority vote to approve the merger by Trubion stockholders at a special meeting conducted at Trubion’s Seattle headquarters on October 28, 2010. The acquisition [...]
In: Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri, Seattle, Trubion Pharmaceuticals, United States · Tagged with: Chief executive officer, Emergent BioSolutions, Fuad El-Hibri, Seattle, Trubion Pharmaceuticals
Emergent BioSolutions to Acquire Trubion Pharmaceuticals
Trubion provides promising clinical-stage therapeutic candidates in the targeted disease areas of oncology and autoimmunity
Trubion offers novel, protein therapeutic platforms and scientific expertise for developing innovative therapeutic candidates
Transaction leverages large pharma partnerships to provide sales and marketing infrastructureidates
Emergent reaffirms 2010 guidance for revenues and net income
ROCKVILLE, Md., Aug 12, 2010 (BUSINESS WIRE) –
Emergent BioSolutions Inc. [...]
In: Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri, Shareholder, Trubion Pharmaceuticals, United States · Tagged with: Biosolutions, Board of directors, Common stock, Emergent BioSolutions, Seattle, Stock, Systemic Lupus Erythematosus, Trubion Pharmaceuticals